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Thrombus formation in the infarct-related coronary artery 
can be demonstrated in the majority of patients with acule 
myocardial infarction (1). and these observations have pro- 
vided a rationrde for tbmmlmlytic therapy in such patients. 
During the last few years there has been an intense interest 
in thrombolyt c therapy for patients with acute myocardial 
infarction based on the strong evidence that such therapy 
can reestablish anterograds bhxd Row in the totally oc- 
eluded coronary artery (2.X. These studies employed the 
mtracoranaw administration of streptokinase or urokinase. 
which resulkd in restoration af blood Row in 60 to 94% of 
patients. Subsequent studies found that streptokinase ad- 
ministered ty the intravenous route can also open occluded 
coronary vessels but in a smrdler proportion of patients than subsequently performed with the infarct-related artery stud- 
by the intracoronary route (2,3l. ied last. The infarct-related artery was restudied after the 
Streptokiuase and umkinase not only induce clot disso- administration of intracomnwy nitroglycerin (ZOO ~1. Pa- 
lution but also activate circulating plasminogen to plasmin, tients with <SO% reduction in the diameter of the infarct- 
which in turn results in the degradation of plasma fibrinogen related artery after intracomnary nitroglycerin were not 
end consumption of alpha,-antiplasmin. The systemic nature given thmmbolytic therapy. Repeat dye injections and cin- 
of this genernlized fibrinolytic state has been considered to eangiography were performed et IO, 20,30,45,f& 75 and 90 
be responsible, at least in pert, for the bleeding associated min afier the stert of intravenous administration of the 
with these agents. Thus. etTorta were made to identify agents assigned ihrombolytic agent. 
that would induce lysis only at the site of thrombus fortna- Treatment pretocel. Each patient was randomly assigned 
tion. A potential agent with these properties, tissue-type in double-blind fashion to receive simultaneously either I) a 
plasminogen activator, was identified and obtained initially 1 h infusion of I .5 million units of rtreptokinase and a 3 h 
from a human melanoma cell line (4). Similar material has infusion of r&PA placebo, or2) e 3 h infusion of r&PA (40 mg 
been successfully produced by recombinant DNA tech- first hour, 20 tug second hour and 20 tng third hour) and a I 
niques (5) and has become available for clinical studies. h infusion of etreptokinaae placebo. Streptokinase and its 
In 1983. the National Heart, Lung, and Blood Institute placebo were supplied by Hoechst-Roussel Pharmaceuticals 
established the Thrombolysin in Myocardial Infarction and Kabi Vitrum (Stockholm, Sweden); Genentech Inc. 
(TIMI) study group in order to assess the efficacy of thmrn- supplied R-PA (Cl 1021. predominantly a two-chain form of 
bolytic agents in the treatment of acute myocardial infarc- the agent) and its placebo. 
tion. This group has completed phase I of the TIMI study, Subsequent coronary core was provided within general 
designed to assess the relative thrombolytic efficacy and side TIMI guidelines. This included continuous intravenous hep_ 
effects of intravenously administered human recombinant erin infusion, which was begun at a dose of 1 ,OM U (USP)/It 
Ii&sue-type plasminogen activator W-PA) and streptokinase at 3 h after the initial bolus. The amount was adjusted 
in patients with acute myocardial infarction and angiographi- according to a standardized protocol to maintain activated 
ally documented total occlusion of the inferct-related cor- partial thromboplastin times of 1.5 to 1 times nomtrd; in the 
onery artery. A preliminary report of the recanalization rates absence of serious hemorrhage, intravenous heparin was 
in patients treated with r&PA and streptokinase has been continued until predischarge cathelerization ,&xnted 8 to 
published (6). The present report summarizzs the compare- IO days later. Care of the puncture site was meticulous, 
tive findings with respect o the bleeding complications and including removal of the arterial sheath 24 h aPier placement, 
the alterations in plasma levels of fibrinogen, plasmioogen with partial tapering of the dose of hepatin. Treatment wkh 
and fibrinloge@ degradation products encountered in pa- dipyridsmole and aspirin was begun before discharge and 
tients treated in phase I of the TIMI study. continued thereafter. All subjects entered into this study 
gave infornted consent, and the study protocol has been 
Methods 
approved by the institutional committees on human re- 
search. 
Selection of p&tents. Entrance eligibility and exclusion ClwIticatioo of hemmrbgic events. In the course of 
criteria, study conditions end details of assessment of coro- pre-phase I TIMI studies. a Mortality end Morbidity Ctessi- 
nary patency rates have been described elsewhere (6.7). tieation Committee was esteblished that reviewed the expe- 
Patients with a30 min of ischendc chest pain end ST rience and the hemoglobin and hetnatocrit !evels in patients 
segment elevation (0.1 mV) in at least two electrocardio- treated before TIMI phase I at three clinical centers. This 
graphic (EC@ leads were eligible for the study. Patients review included patien,s treated in the TIM1 open label 
were not eligible for particbation if more than 7 h had studies with rt-PA and atreotokinase. and oatients with acute 
elapsed sin&the onse; of chest pain. Additional exclusion 
factors were age >75 years, uncontrolled hypertension, a 
recent cerebravascular event, known hemorrhagic dir&h& 
or active hemorrhage, recent treatment with streprokinass, 
recent strcptococctdl i fection, prior coronary alery bypass 
grafting, prolonged cardiopulmonary resuscitation, shock 
unresponsive to volume expansion end intravenous vildo- 
pressers. or other known serious ilhws. 
Eligible mnarnting patients were taken to rhe cord’ae 
corhevrizarion laborarmy end given intravenous heparin 
lS.CJXl U) after placement of an arterial sheath. Left vetxri- 
culography was petfornted. Coronary arteriognphy wns 
myooerdiel infarction whdhed not receivid any thromboly- 
tic agents. It was concluded that a decrease in hemoglobiu of 
3 gidl (or in hematocrit of 10%) could be seen with en 
uncomplicated clinical course in patients who had ttot re- 
ceived thrombolytic therapy, and that bleeding that was 
clinically severe because of loss of blood volume was found 
in patients with a decrease in hemoglobin of 5 g,dl (er in 
hematocrit of 15%). The following observations were also 
taken into account in formulatinE the classification criteria: a 
latge emount of blood was draw; for laboratory tests (SW 
ml not including the initial dead space blood discarded 
during drawing from intravenous or intraarteriul catheters), 
and hemoconcemration and initial increase in hematocrit 
occur early with the onset of acute myocardial infarction. 
Without knowledge of treatment assigomentx the Clarsifi- 
cation Committee reviewed case reports of all panems 
treated in ohase I who had a blood transfusion. a decrease I” 
hentoglob;” S3.0 p/d1 or an observed blood loss. 
The bleedins was classi(ied as maior if it was intracranial 
or awxiated with a decrease in hemoglobin ~5 gidl (or 15% 
in hematocrit,. The bleediw was cons~dcrcd minor if I) I, 
was spontaneous and observed as gross hematuria or hema- 
temesis, or 2) if blood loss was observed lfor example. 
heme-positive cotTee ground em&. heme-positive melena. 
hematoma or retropentoneal bleeding). whether spontane- 
ous or nonspontaneous, with the hemoglobin decreasme: >3 
gidl (or her&o& decreasing at least &I. Patients with a 
disregarded as indistinguishable from the background of 
decrease in hemoglobin >4 gidl (or 12% in hematacrit) with 
no bleeding site identified despite an eiion to find one were 
phlebotomy. rehydration and ecchymoses attendant on inn- 
classified in the group with “blood loss wdh no site idemi- 
fied.” For the purpose of the analyses these patients are 
sive procedures. Pallems with hemorrhagic events were also 
counted as having had minor hemorrhagic events. The 
primary site of bleeding was classified as unknown when 
classified according to the primary site of blood loss and 
naneoftheobserved sitesofbload losscouldaccount forthe 
magnitude of decrease in hemoglobin, or when it was not 
possible to disringuish which of the several bleeding sites 
was primarily responsible. Transfusions were factored into 
the evaluation of blood loss as one unit of packed cells or 
whole blood accounting for 1.0 gidl hemoglobin. Suspected 
blood loss that did not meet criteria for minor bleeding was 
ugation. The plasma and serum samples were frozen at the 
indiwdual centerr at -20°C and were shipped on dry ice to 
the Coagulation Core Laboratory. where they were stored at 
-70°C until the time of the assay. 
the Thr&bo-Welleotest method using latex panicles sosteb 
with antibodies against fibrinogen fragments D and E (Well- 
Samples were analyzed at the initial thawing of the 
plasma camples. Because of the presence of heprin in 
come Diagnostics. Dartford. England). 
plasma. fibrinogen concentrations were assayed by the 
melhod of Man&k and Beny IS). which measures precipk- 
Statistical metkds. Percentages and proportions were 
able fibrinopen. Plasma plasminogen activity was measured 
by the method of Fribe&er and&x (9, &g a chmmo- 
genie substrate. S-2251 (Kabi Diagnostics. Stockholm. Swe- 
den). The results are expressed as a percent of activity in 
relation to that in pooled normal plasma taken as IOZ%. The 
fibrkdoaen) deer&&n oroducts levels were measured bv 
secondary, contrib&ing bledding &es, when identified. compared for probability of diffeiences due to chance using 
Measurement cd p,ne.ma levels of Abrbwen. plamdnoxen standard Z-tests. With respect o the mean plasma levels of 
and Ibrin(ogen, d&dalion pro&b. The ?oag”latio” 
search Center, Temple University. Philadelphia. Pennsylva- 
oia. to assess the changes in plasma levels of fibrinogen. 
Core Laboratory was established at the Thrombosis Re- 
plssminogen and fibrkdogen, degradation products. Blood 
samples were collected before. at 3.5 and 21 b, and at 8 to 
IO days after the initiation of drug infusion. For the mea- 
suremen, of fibrinogen levels, blood samples were collected 
into tubes contailing 0. I volume of 0.01 M sodium citrate 
and 250 U/ml of a ontease inhibitor. aorotinin ITrasvlol. 
FBA Phammcestic&,; for plasminoge~. they were .coI- 
lected into tubes containing only 0.01 M sodium citrate. The 
plasma was harvested by centrifugalion at 1,500g for 20 min. 
For measurement of fibrirdwen, degradation products, 2 ml 
aliquots of blood were collected into tubes obtained from 
Bectoon-Dickinson. containing thrombin (20 NIH units,. and 
soybean trypsio inhibitor (3670 NF units) to which 58 pg of 
protamine sulfate (Eli Lilly) had been added to neutrakze the 
heparin presem in the plasma. The blood was allowed to clot 
at 3PC for 30 min and the serum was harvested by centrii- 
fibrinogen, plasminogen and fibrinlogen) d&datirm prod- 
past-!reatment comparisons were made with a paired r test. 
UC&. the data were analyzed using Student‘s r test. Pre- to 
Correlation coefficients and p values were based on regrer 
sion for linear trend (10). A8 statistical tests were performed 
wing the BMDP statistical software package (I I,. 
R~IJ1t.S 
Two hundred ninety oatienta with acute myoeardial in- 
farction were treated &Fording to random a~&nment with 
n-PA (143) or streptakinase 1147) in TIM1 pbaae I. The 
findings with respect to the coronary recanalization rates 
have been published elsewhere (6.7,. 
Untoward eve& othtr than bawrb@c epiwdrs zmd 
cardisccomplieatimwccwringdwin8 tke 6Rt 24b (Table I). 
A rimrificant difference was seen only in the incidence of 
feve; or chills. which occurred in 6 i4.2%, and 22 (15%) 
patients treated with rt-PA and streptokinase. respectively 









sodes. There were no significant ditTerences in the frequency 
of hemorrhagic omplications or in the distribution of pri- 
mary bleeding sites between the two gmups. In >70% of 
patients with bleeding events in both groups, the primary 
bleeding site was et the paint of puncture for cardiac 
catheterization or other vesculer access. There were no 
episodes of intracranial bleeding. In four patients (one in the 
&PA group, three in the streptokinase group) the primary 
bleeding site wes in the gastrointestinal tract: in two of these 
patients (streptokinese) the bleeding occurred in the first 24 
h of therapy and in the others (one R-PA-treated, one 
streptokinase-treated) it occurred later in the hospital 
course. In 14 patients (nine tt-PA-treated. five streptoki- 
n&se-treated) the primary bleeding site was not identified. 
shy of streptokinase to evoke such reactions in individuals 
previously exposed to streptoc~~us. There wele no in- 
stances of anaphylaxin in either group. 
Hemorrhagic wents (Table 2). Pad&s with hemorrhagic 
comolicaliuns were ciarsified, based on criteria described 
under Methods, into those with major and minor hemor- 
rhage. and according to the sites of bleeding that were 
assigned in each patient as the primary or contributing site of 
blood loss. In the CPA group, 47 patients (32.9%) tad 
homorrhegic events; 22 patients (IS.4%) were classified as 
having had maior and 25 (17.5%1 as havine had minor 
hemorrhagic w~plications. In the streptoki& group, 46 
patients (31.3%) had hemorrhagic episodes; 23 (15.6%) had 
major events and 23 (1X6%%) had minor hemorrhagic epi- 
Several of rhe poriem had IWO m more bleeding sires. 
one clmsifred (IS the primary sire end rhe orheo ar cowib- 
uring sires. lwn’ing the distinction between primary and 
contributing sites, 7 rt-PA-treated patients (4.9%) and 10 
streptokinase-treated palients (6.Z3%) had gestmintestinal 
hemorrhage. However, the nastrointestinel tract was the 
primary &e of bleeding in-only four patients (one z-t- 
PA-treated, thnx streptakinase-treated) (Table 2). Like- 
wise, 39 rt-PA-treated patients (27.3%) and 40 streploki- 
nasetreated patients (27.2%) had hemorrhage from the 
catheterization site of which 34 (23.8%) in the r&PA group 
and 33 (22.4%) in the streptokinase group were considered 
the primary sites. Fourteen patients Wee rt-PA-treated, five 
stre~toki&e-treated) had either gross or microscopic hema- 
turia; in only one patient (rt-PA-treated) was this the pri- 
mery site of blood loss. The distribution of the secondary 
contributing bleeding sites wea found to be similar in both 
treatment groups. 
There wm one death attributable to bleeding complica- 
tions. The patient, treated with CPA. developed a pericar- 
dial friction rub on the 3rd day. leading to thk dis&tinua- 
[ion of heparin infusion and the start of aspirin and 
dipyridemole therapy. Over the next few days he developed 
melanotic sto& due to B gastric ulcer that eroded thd gastric 
artery, and he died during emergency gastric resection. 
A lofal of 32 parienrs (22%J in ihe CPA group and 29 
padenfs (20%) in the slrqmkinosc group received blood 
Table A Changes in Plasma Fibrinogen. Plasminagen and FibrinCog@ Degradatmn &ducts in 254 Patienta 
pre 3h 5h ?lh Diwhargc 
Fibdnopn 
transfusions for the ~eornwnt of hemorrhagic evena (p = 
nr) fTobIe 3). The frequency of VMsfusions in the r&PA and 
streptokinase groups was not significantly diErent. Nine 
patients in the rt-PA group and 10 in the srreptokinase group 
received blood transfusions in relation to procedures such as 
coronary artery bypass graft surgery and percutaneous 
hansluminal coronary angioplajty. or for concomitant dis- 
orders such as the anemia of collagen vascular disease or 
chronic renal failure. 
chpnges in plaws levels of fdxinogen, plaania and 
libria(o@t) @Mation pndoeb (Tables 4 and 5). Adequare 
blood samples for the measurement of plasma levels of 
fibrinogen, plasmioogen and fibrin(ogen) degradation prod- 
ttcts were available from X35% of the patients entered intc 
the trial. In the remaining patients, blood samples were 
Plusmu&ino~@s levels declined significantly after treat- 
ment with n-PA and with rtreptokinw (Fig. IA, Table 4); 
however, the pOst-treatment levels were significantly lower 
in the streptokinaEe-treated patients than in the fl- 
PA-treated patients. Althaugh the levels in rt-PA-treated 
patients at 3.5 and 27 h declined on the awrage by 26.33 aId 
I I%, respectively. the cornspading levels in stre~!~kinase- 
treated patients declined on the average by 57.56 aid 21%. 
The greater decline of fibrinogen in patients treated with 
streptokinase is further demonshated in the relative distri- 
butian of patients with fibrinogen levels Cl50 mgidl and 
<lOD meldI (Table 9. In the CPA wow. 4 (3%) of 123 
patients-had fibrinogen levels of <I& r&d1 at 3 h after 
initiation of therapy compared to 37 (30%) of 125 patients in 
the streptokinare group (p < 0.01). At the time of hospital 
dischwze the fibrinaeen levels were markedlv elevated corn- 
pared &h pretreat&d values in both &ups of patients 
(Fii. IA, Table 4). 
The decline in plasma p~orminogen levels WJ greater in 
porients treated with srreptokinase rhon in dose receiving 
n-PA. After initiation of n-PA. plasma plasminogen levels 
decreased from L mean of 100 e 2% before infusion to 36 r 
I% (p < 0.01) at 3 h, and to 42 r I% (p c: 0.01) at 5 h (Fig. 
IB. Table4). At27 h themeanlevel(61? l%)was stilllower 
(p < 0.01) than the pretreatmenr value. In patients treated 
with streptokinase, the corresponding mean levels a, 3.5 and 
27 h were I6 + I, I6 f I and 41 i I%. respectively (Fig. 18). 
A, ,he time of hospital discharge, the levels were elevated (p 
< 0.01) compared with pretreatment levels in both groups. 
The levels ofplasmofibrin(ogenj dt~gradation products at 
3 h rose from prerreatment mean values of 3 + I and 6 t 3 
to 111 f I2 and 257 r I2 pglml in the e-PA and the 
streptokinase group, respectively, and remained elevated at 
5 and 27 h (Fig. IC. Table 4). At all three time poims. the 
circularing fibrin(ogen) degradation products levels were 
higher tp < O.WI) in rtreptokinase-treated patients. 
The rehlion berween plosmo levels offibrinogen. plas- 
minogen nndgbrinfogen) degrad&a products nr 5 h after 
the start of therapy and hemorrhagic events (m&r or 
minor) (Tables 6 10 8). Table 6 shows the correlation 
coetliciems: in both treatment groups, the stronger, relation 
were noted with plasma levels of tibrin(ogen) degradation 
products that showed correlations with hemorrhage unlikely 
to have occurred by chance W-PA. P = O.W2: streptokinase, 
Figure 1. Changes in plasma levels of fibrinogen IA). plasminwn 
(B)and Sbrin(ogen)degmdation pr ducts (CI in patients reated wi,h 
recombinant tissue-type tasminogen activator WPN and strepto- 
kinane (SK). Shown are mean vatws t SE. The numerals in 
parentheseo r present rhe number d paritnrr. The p values indicate 
the level of signiticancc forcompmirions between the two treatment 
arms. For compalisons within each treatment group. the levels of 
Sbrinogen (A) and plasminogen (g) a, all time pOints were signifi- 
cantly (p < 0.01) di&rent from pretreatment values; the levels of 
Lbrintogen) degradation products (C) were signihcamty different tp 
< 0.02) fmm metreatment values at 3.5 and 27 h but no! at the time 
of hospital discharge 
levels were not so striking. However, the correlations were 
stranger between hemorrhagic events and the percent 
change from pretres,men, level in plasma librinogco in the 
r&PA group (r = 0.274, p = 0.003) and the percent change in 
plasminogen level in the streptokinase group (r = 0.203. p = 
0.03). 
Table3 7 and 8 show the proportion of patients with 
hemorrhagic evenls at ditTerent plasma levels of fibrinogen, 
plasminogen and fibrin(ogen) degradation products at 5 h 
after start ofthrombolytic therapy. In general. the frequency 
of hemorrhage was higher in patients with greater changer in 
plasma. Among patients treated with rl-PA, hemorrhagic 
events were observed in 29% of Patients with fibrinogen 
levels 8250 mg/dl compared with 60% of patieds with 
fibrinogen levels of 5149 mgldl (Table 7). The frequency of 
hemorrhagic events in patients with plarminogen levels 850. 
20 10 49 and ~19% WBF 23, 35 and 40%. respectively. 
Fibrin(ogen) degradedan products levels of 0 to 99 &ml 
were associated with hemorrhagic events in 26% of patients: 
p = WlU3). The relattons to plasmtnogen and fibrinogen this Percentage increased to 45% in patients with levels of 
03 to 399 pg!m, and to 60% in patients with levels >4OO 
&ml. In patients treated with streptokinase (Table 8) the 
gradient was not impressive with respect to fibrinogen lev- 
els. The occurrence of hemorrhage increased from 18% in 
patients with plasminogen levels of 20 1049% to 33% in those 
with plasminogen levels of 0 to 19%. The relation to the 
levels of tibrin(ogen) degradation pmducts wa impressive; 
hemorrhagic events occurred in 24% of patients with fibrin- 
(open) degradation products levels of IO0 to 399 &ml and 
rose to 48% in patients with higher levels. 
The relorionship berween plnsmo jibrinoge,,, p,md,,o- 
gen ond/ibrin(ogenJ degradation products CC, 5 h IO s:,ccess- 
ful rep&&m of the tol& occluded army and reocclurion 
of the reconstilufed artery. Within each treatment group 
there were no major diierences in the plasma levels of these 
Trhk 7. Reladon of Plasma Fibrinogen. Plasminogen and 
Fibrinogen Degradation Product Levels at 5 h to Occurrence of 
Hemorrhage in 124 Patients Treated With Recombinant Tissue 
Plasminogen Activator 
proWin\ between those whose artery was reperfused and 
those whose artery was not. or between those developing 
reoccluion verws those maintaining vessel patency (not 
shown). Interestingly. in the rl-PA group, the percent de- 
cline III fibrinogen from pretreatment levels was less m 
patients with reperfusion (3, + 3%. n = 59) than in those 
without reperfunion (4, + 4%. n = 33; p c 0.05). 
Thrombocytapeoia. After initial mearurement, the fre- 
quency of platelet coonts was determined by individual 
participating centers. Platelet coonts 415O.woIp were en- 
countered in 14 patients (II r&PA-treated. 3 streptokinase- 
treatedl. In wen of these patients, there was an explanation 
for the ,ow platelet cooots. Two patients (both in the n-PA 
group, had pretreatment platelet cooots <,50.0,0,~,. In one 
of them. the platelet coonts Roctuated bewee,, lOJUX”I,~ 
and I5O.oM!~l for several days with megathrombocytes and 
platelet clumps being noted on the peripheral smear. In the 
second pataent the platelet count was ,,7,WNlpl ot admis- 
sion, declined LO 25.OW~l on the 6th day. and recovered to 
134,OWpl at the time of discharge; the platelet coom 6 
weeks later was 97.wOlpl. lo one patient (rt-PA groopl there 
was a transient decline (on a single observation) in the 
platelet coont to 136.000/pl on the 41h day with a normal 
count the next day. In three patients frwu rt-PA-treated, one 
streprokinase-treated) the thrombocytopenia was noted in 
relation to a cardiopulmonary bypass procedure. In one 
patient (n-PA group) with B history of lupus nephritis and 
treatment with azathioprine. the platelet coont declined to 
<liM,CQOi~l on day 3 with rapid recovery in the next 24 h. At 
Tabk 8. Relaooo of Plasma Fibrinogen, Planmioogen and 
Rbnnogen Degddatioo Product Levels at 5 h to Occurrence of 
Hemorrhage in 122 Patients Treated With Streptokinase 
this time she bad bleeding problems and deterioration of 
renal function. 
In the remaining seven patients (five rt-PA-treated, two 
streptokinase-treated). thrombocytopenia was first noted 
between days 3 to I3 of hospitalization and remained 
<150.tNO/oo/lrl f r 2 to 6 davs in six oatients and for 22 days in 
one, ln to& of these p&ots the iowest mounts ranged from 
3tl.Mo10 53.OW~: the thrombocytopenia WRS considered as 
powbly related to heparin therapy in three, and the founh 
patient had acute cholecystitis and was taking multiple 
antibiotics. 
Hemorrhagic even15. The major untoward elfecl cneoun- 
tered in mis trial is the high incidence of hemorrhagic events 
in both treatment groups. In previous studies (2) the frc- 
qucncy of such events in patients administered a high dose, 
short-term intravenous infusion of streptokinase has been 0 
to 21%. In the present study hemorrhagic events occurred in 
33 and 31% of patients treated with SPA and streptokittase. 
respectively, and there was no difference in the frequency of 
mgor or minor hemorrhagic episodes (Table 2) or in tram- 
fusion requirements between the two groups (Table 3). For 
>70% of the patients with hemorrhagic events in each 
treatment group, the primary bleeding sites was the cathe- 
terizatton site or other puncture sites. In only four patients 
(one n-PA-treated, three streptokinare-We&d) war the 
primary bleeding site in the gastrointestinal tract. In the 
European Cooperative Study (12), bleediog complications 
were predominantly at the catheterization and puncture 
!sites: 27% of R-PA-treated natients and 52% of streotoki- 
nase-treated patients develo~d such complications. ‘Thus. 
avoidance of invasive procedures in these patients may 
reduce the hemorrhagic CYCIL~S. 
In LLeorinp rhe rriolosv offhe bleed!ne mon$esrations 
sewmifactnr.~ need IO be ;;n;ide,ed. I) Ali patients under- 
went anticoagulation with heparin; vigorous anticoagulation 
in the face of arterial punctures would be an important fttdnr 
in the high incidence ok puncture site hemorrhage. 2) The 
relation between the bleeding manifestations and the throm- 
bolytic agents is complex. and at least two distinct mecba- 
aiamb wnant consideration: the effects of these agents in 
dissolving fibrin clots. and their action on plasma proteins 
leading to the generation of tibritdogen) tcgradation pmd- 
ucts. Adminiitration of either thromholytic agent would 
dissolve fibrin clots not only in the coronary arteries but also 
at silts of vwalar breach where clot lysis would lead to 
hemorrhage. The generalized dirsolution~of clots with even 
relalively fibrin-wecific agents dictates the wed for careful 
selec!ion of patients for such treatment. 3) FurtIter. both 
n-PA and strcptokinase lowered fibrinogen levels with ele- 
vation of fibrin(ogen) degradation products in the circulation 
(Fig. I). In both treatment groups, the frequency of hemor- 
rhagic events was higher in patients with greater changes in 
the plasma protein (Tables 7.6) and a relation was noted 
between the le~?els of fibrin&en) degradation products and 
bleedicg episodes (Table 6). In patients treated with It-PA. a 
significant relation was observed between the reduction in 
fibrinogen levels and bleeding events (Table 6). The soluble 
degradation products of fibrinogen and fibrin can impair 
fibrin polymerization (13,141 and thereby function as anti- 
coaeulants. Moreover. ther may inhibit platelet 114). as may 
&dating plasmin (IS) anb the-angiogiphic contrast media 
(16.17). 4) Overrdl. the high incidence of bleeding. psrticu- 
larly ar the puncture sites, is attributable in large part to the 
study protocol including the doses of the thmmbolytic 
agents, the simultaneous and prolonged administration of 
heparin. and vascular invasion. 
Changes in plasma lwrls offibrinogen. plasminogen and 
fibrin&en) degradation products. Our studies indicate that 
rt-PA and streptokinase induce changes in the levels of these 
plasma proteins to a different magnitude. The changes in 
these proteins are interrelated with each reflecting the inten- 
sity of the systemic ftbrinogenolytic state. At 3,5 and 27 h, 
the plasma levels of fibrino&z 2r.d plasminotw were signif- 
icantly lower and those of tibrin(ogen) degradation pmducts 
were higher in patients treated with streptokinase than with 
administered rt-PA (Fig. I). These observations are similar 
to those in our previous smaller and unblinded studies in 
patients treated with it-PA and streptokinase (16.19) and 
those of the European Cooperative Study Group W. They 
establish that at the doses used, intravenous administration 
of n-PA over 3 h results in less perturbation of circulating 
levels of the measured proteins than occurs when streptoki- 
nase is administered over I h. 
&xeb even wild SPA are of sufficient magnitude to impair 
hemostatic mechanisms. The implied contribution of the 
plasma changes to the hemorrhagic events is supported by 
the observed increasing frequency of hemorrhagic events 
with greater changes in plasma in patients of bath treatment 
groups (Tables 6 to 8). However, other factors. including 
anticoagulation and invasive procedures. also contribute to 
the hemorrhagic events and may he impotiantdetcrminants. 
The changes nored in the plamma of patienrs treated with 
n-PA provide slrong evidence for rke activrrlion ofplasmin- 
ogcn IO plusnun in the circularion and occurrence of n 
svsrrmic fibrincvenolvric stole. Our findiws are similar to 
those of Topol et al: (20) and the Burop&.o Cooperative 
Study Gmup (12) and refleel a tnor~ itttense systemic effect 
than reported in earlier studies in patients (21-23) and 
animals W-26) in which either no changes or smaller 
changes were noted in the plasma factors after administra- 
tion of tissue-type plasminogen activator, This discordance 
thrombolytic agent in the etiology of the thrombocytopenia 
encountered. Future prospectwe qmdies would need to 
address ‘iis aspect. 
may be related to a number of factor, includiw rhc rmaller 
doses of CPA administered in the other rtudiei. Gkercoccc 
in the methodologies used to measure fibrinogen lk~els and 
species diffwences. One possibdity to be considered is 
whether the plasma changes noted m our patieotr treated 
with n-PA are artifactual. arising in vitro because of an effect 
of the circulating n-PA after the blood samotes have been 
drawn. To obviate such an effect. blood s;mples for ,bc 
measurement of fibrinogen levels were collected in tuber 
containing an cxcoss of the protease inhibitor, aprotinin. 
Measurements were also made in samples obtarned at 5 h, 
that is, 2 h after the end of r&PA infusion and 24 h later. In 
human subjects. the initial circ~lahog half-life of a-PA in 
plasma after cessalion of dros infurion is 6 min ,271 Tbcre- 
fore, the late samples wxdd cooiain mimmel amounts of 
circulating rt-PA to induce in vitro Rbrinogenolysis, parte- 
u!arlv in the oresewe of an excess of omtease inhibitor. 
h&over. dir&t measurements of plasma fibrinolytic activ- 
itv usine tubes coated with ‘“‘i-Gblin w~ealed neelieible 
e&y% the samples obtained at 5 h from rt-PA-kkd 
patients (28). At 5 h, the fibrinogen and plaeminogen levels in 
rt-PA-treated patietis showed average declines of 33 and 
57% -*‘-~*;ve!y, arrd they were significantly lower than , ._ll__.. 
Conclusions. The predomirant untoward ekct in !his 
study bat been the bigb mctdence of hemorrhagic wents that 
were comparable m both gro”ps and occurred primatily at 
catheterization and other puncture sites. These F.ndiogs 
dictate the need for avoidance of invasive procedures and for 
mrtichious care in the seleaion snd managemem of patients 
subjected to thrombalytic therapy. Further, although both 
n-PA and streptokinaee were noted to induce systemic 
tibrinogenolya. this was significantly less intense with 
n-PA. To&mr with the previously reported (6.12) hi&r 
coronary reperfosion mtcs among Ir-PA-tremed palients. 
!bcrs Indioeq wgg?st the superiority of n-PA in the thmm- 
bolytic therapy of patients with acute myocardnl mfarctios. 
pretreatment levels even 24 h later. Thus, the changes noted 
reflect a true in viva systemic effect of rt-PA on the plasma 
proteins. 
The decline in fibrinogen levrls in onr patients mated 
with srreotokinosr IS comwrable to that reooned recentlv bv 
Metttzer’et al. (29) but I&s than in other‘studies (30.3il t; 
patients with acute myocardial infarction. The lauer ditfer- 
ence is pmbably due to differences in the methods used for 
the measwement of plasma fibrinown and the absence of 
proteolytic inhibit&in the plasma samples to prevent in 
vitro tibrinogenolysis. Because of the known effect of hepa- 
tin and the tibrin(o@,en) degnrdatton products on ass& 
based on rate of blood caegulation. we used a technique (8) 
that ouantjtates the ~~ecioitabk librino%en in okma. Such 
methods underesti&e the decline id fibrin&en) becausr 
fragments X and Y are also precipitated. In contmst, aszays 
based on thrombin clotting of fibrinogen may overestimate 
the decline due to the anticoagulant action of heparin and 
tibrin(ogen) degradation products (13). The influence of the 
assay methods is demonstmted in studies (12.32) measming 
fibrinogen levels simultaneously by multiple techniques. 
TItmmboeytoPetda. Fourteen patients entered into this 
study d&eloped thrombnxytopenia platelets (<ISO,lW~I). 
In three patients it occurred in relation to cardiac sm’gery 
and in three others it was considered to be related to heparin. 
All of the patients were receiving multiple drugs including 
heparin. a dmg well recognized to cause thrombocytopenia. 
and some patients had other contributine factorr such 1s 
bemonhag~, infectiin, collagen vascular disease and mar- 
row suppressive therapy. Given the complex clinical situa- 
lion, it-is ditlicult to h&ermine the role; if any, of either 
Bsyw CMlcgc of Medicin+, Hamton. TX. Principal Investigator: Robert 
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